Now NICE Recommended1
TECENTRIQ in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or mTNBC whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease2
Immune Checkpoint Inhibition in mTNBC – UK IBCS 2020 Symposium Highlights
These highlights are taken from the filmed Roche-sponsored promotional educational symposium during the UK IBCS in Birmingham on 27th January 2020.
Dr Javier Cortes, Prof Peter Schmid and Dr Melissa Phillips recap recent advances in the management of mTNBC and areas of ongoing research, explore the use of immune checkpoint inhibitors in the treatment of mTNBC and discuss potential immunotherapy-related toxicities, incorporating their own experiences within clinical practice through patient case studies.
To access this content, please sign in or click here to register.
AE, adverse event; HRQoL, health-related quality of life; IBCS, Interdisciplinary Breast Cancer Symposium; mTNBC, metastatic triple-negative breast cancer; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival.
References:
- National Institute for Health and Care Excellence. Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer [TA639]. July 2020.
- TECENTRIQ Summary of Product Characteristics. Available at www.medicines.org.uk/emc/product/10697/smpc.
M-GB-00001324.
Date of preparation: September 2020.